Patheon to Highlight Services and Capabilities at Prominent Industry Conferences

Top scientific experts at Patheon®, a leading provider of contract development and commercial manufacturing (CDMO) services to the pharmaceutical and biotechnology sectors, will be presenting at two upcoming industry events.

Paul Sabo, senior scientific leader, early development, will highlight Patheon’s preformulation and formulation development approach at the Fourth Annual Drug Formulation and Bioavailability Conference in Boston on Tuesday, Jan. 27, at 4:15 p.m., at the Hilton Boston Logan Airport hotel. Widely regarded as a thought leader in product development services, Sabo will be presenting “Stepwise Approach to Preformulation and Formulation Development to Maximize Success,” emphasizing the importance of understanding target product profile and physico-chemical properties, to developing formulation approaches for Phase 1 studies and dealing with solubility limitations.

In addition, Kevin M. Kane, PhD, applied technology director, will showcase the Patheon OneSourceTMintegrated, end-to-end offering at the Drug Delivery Partnerships (DDP) Conference in Boca Raton, Fla., on Thursday, Jan. 29, at 1:30 p.m. Dr. Kane is presenting “Patheon OneSource™: An Integrated Solution - Development through Commercial Supply,” highlighting Patheon's ability to leverage efficiencies in both API and product development, reducing the time from molecule to market and providing value to emerging and mid-size customers. Patheon OneSourceTMcapitalizes on an integration of speed, simplicity and quality expertise, delivering an industry-leading customer experience from early development through to commercial manufacturing.

Digital copies of both presentations will be made available for download by visiting http://info.patheon.com/2015-January-thought-leaders. 

Patheon Media Relations

Tel: +1 (919) 210-0986

Email:  tyler.gronbach@patheon.com or media@patheon.com

About Patheon®

Patheon, a business unit of DPx Holdings B.V., is a leading provider of contract development and commercial manufacturing (CDMO) services to the pharmaceutical and biotechnology sectors. The company offers one of the broadest sets of solutions to customers including commercial manufacturing, drug product services, biologics, pharmaceutical product development services and active pharmaceutical ingredients (API). With a reputation for quality, scientific technical excellence, the company has more than 20 locations and 8,000 employees across North America, Europe, Latin America and Australia. For more information, visit http://www.patheon.com.